| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6113944 | APOTEX | Paroxetine tablets and process to prepare them |
Dec, 2014
(9 years ago) | |
| US5872132 | APOTEX | Form of paroxetine hydrochloride anhydrate |
May, 2015
(8 years ago) | |
| US5900423 | APOTEX | Form of paroxetine hydrochloride anhydrate |
May, 2015
(8 years ago) | |
| US6133289 | APOTEX | Paroxetine hydrochloride form A or C |
May, 2015
(8 years ago) | |
| US6080759 | APOTEX | Paroxetine hydrochloride form A |
May, 2015
(8 years ago) | |
|
US6113944 (Pediatric) | APOTEX | Paroxetine tablets and process to prepare them |
Jun, 2015
(8 years ago) | |
| US5811436 | APOTEX | Oral liquid compositions containing paroxetine resinate |
Sep, 2015
(8 years ago) | |
|
US5872132 (Pediatric) | APOTEX | Form of paroxetine hydrochloride anhydrate |
Nov, 2015
(8 years ago) | |
|
US5900423 (Pediatric) | APOTEX | Form of paroxetine hydrochloride anhydrate |
Nov, 2015
(8 years ago) | |
|
US6133289 (Pediatric) | APOTEX | Paroxetine hydrochloride form A or C |
Nov, 2015
(8 years ago) | |
|
US6080759 (Pediatric) | APOTEX | Paroxetine hydrochloride form A |
Nov, 2015
(8 years ago) | |
|
US5811436 (Pediatric) | APOTEX | Oral liquid compositions containing paroxetine resinate |
Mar, 2016
(8 years ago) | |
| US6121291 | APOTEX | Paroxetine in the treatment of depression associated with withdrawal from heroin abuse and post-traumatic stress disorder |
Mar, 2017
(7 years ago) | |
|
US6121291 (Pediatric) | APOTEX | Paroxetine in the treatment of depression associated with withdrawal from heroin abuse and post-traumatic stress disorder |
Sep, 2017
(6 years ago) | |
| US6172233 | APOTEX | Process for making paroxetine |
Jan, 2018
(6 years ago) | |
|
US6172233 (Pediatric) | APOTEX | Process for making paroxetine |
Jul, 2018
(5 years ago) | |
| US6063927 | APOTEX | Paroxetine derivatives |
Apr, 2019
(5 years ago) | |
|
US6063927 (Pediatric) | APOTEX | Paroxetine derivatives |
Oct, 2019
(4 years ago) | |
Paxil is owned by Apotex.
Paxil contains Paroxetine Hydrochloride.
Paxil has a total of 18 drug patents out of which 18 drug patents have expired.
Expired drug patents of Paxil are:
- US6113944
- US5872132
- US5900423
- US6133289
- US6080759
- US6113944*PED
- US5811436
- US5872132*PED
- US5900423*PED
- US6133289*PED
- US6080759*PED
- US5811436*PED
- US6121291
- US6121291*PED
- US6172233
- US6172233*PED
- US6063927
- US6063927*PED
Paxil was authorised for market use on 29 December, 1992.
Paxil is available in tablet;oral, capsule;oral, suspension;oral dosage forms.
Paxil can be used as posttraumatic stress disorder, depression, obsessive compulsive disorder, panic disorder and social anxiety disorder.
The generics of Paxil are possible to be released after 23 October, 2019.
Drugs and Companies using PAROXETINE HYDROCHLORIDE ingredient
Market Authorisation Date: 29 December, 1992
Treatment: Depression, obsessive compulsive disorder, panic disorder and social anxiety disorder; Posttraumatic stress disorder
Dosage: TABLET;ORAL; SUSPENSION;ORAL; CAPSULE;ORAL
PAXIL family patents
